Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22274929 | 0.82 | GAA (0.33) | MEN1POLBKMT2APDCD1CD274 | |
| SCHEMBL2583995 | 0.80 | — | — | |
| SCHEMBL17009537 | 0.77 | GRIN2D (0.33) | MEN1POLBKMT2APDCD1CD274 | |
| SCHEMBL12245632 | 0.76 | — | — | |
| SCHEMBL23883673 | 0.76 | ALOX15 (0.31) | — | |
| SCHEMBL18497005 | 0.76 | ALDH1A1 (0.36) | ALDH1A1LMNAMAPK1 | |
| SCHEMBL23480264 | 0.74 | PDCD1 (0.35) | MEN1POLBKMT2APDCD1CD274 | |
| SCHEMBL4115988 | 0.74 | USP2 (0.30) | ALDH1A1LMNA | |
| SCHEMBL31643117 | 0.72 | CYP2D6 (0.56) | MEN1POLBKMT2AALDH1A1KDM4E | |
| SCHEMBL16987755 | 0.71 | SLC6A2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017184934-A1 | FORMULATIONS OF AN LSD1 INHIBITOR | INCYTE CORPORATION (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20170304282-A1 | FORMULATIONS OF AN LSD1 INHIBITOR | INCYTE CORPORATION | 2017-10-26 | — | — | US | disclosed |
| WO-2017027678-A1 | SALTS OF AN LSD1 INHIBITOR | INCYTE CORPORATION (US) | 2017-02-16 | — | — | WO | disclosed |
| US-20170044101-A1 | SALTS OF AN LSD1 INHIBITOR | INCYTE CORPORATION | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304282-A1 | FORMULATIONS OF AN LSD1 INHIBITOR | KDM1A, KDM1B, KDM2A | MEN1 1986/4885POLB 3292/4885KMT2A 21/4885 |
| US-20170044101-A1 | SALTS OF AN LSD1 INHIBITOR | KDM1A, KDM1B, KDM2A | MEN1 1874/4885POLB 1167/4885KMT2A 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.